Page 25 - MemoriaEHD-Eng

www.ciberehd.org

P5. Gastrointestinal and Hepatic Oncology

é

Coordinator:

Jordi Bruix

Assistant Coordinators:
í
Jos Juan Garca Marín, Antoni Castells

Research Groups:

1- Experimental hepatology and drug vectorization. Antitumor chemotherapy

resistance. (Dr. JJ García Marín. Univ. of Salamanca)

2- Molecular Pharmacology and Experimental Therapies. (Dr. M. Pastor. Univ. of

Barcelona)

3.- Gastrointestinal and Pancreatic Oncology (Dr. A Castells. IDIBAPS)

4.- Colorectal and Gastroesophageal Cancer. Peptic Acid Disease (Dr P. Parrilla.

Univ. of Murcia)

5.- Hepatic Oncology (Dr. J Bruix. IDIBAPS);

6.- Experimental Hepatology and Gene Therapy (Dr. J Prieto, CUN).

The research is focused on epidemiology, molecular mechanisms, diagnosis and
Description
treatment of liver cancer and cancer of the digestive system. It covers the following
lines of research

1. Cellular resistance to chemotherapy and membrane transport.
13
The low response of liver and gastrointestinal tumors to pharmacological 20
T
therapy is the result of a multifactorial phenomenon involving different me- OR
P
chanisms of chemoresistance (MoC). These mechanisms are classified in RE
five groups according to whether they entail a reduction of the net amount L
A
of drug inside the cell due to a reduction in uptake (MOC-1a) or increase in NU
efflux (MOC-1b), a reduction in metabolic activation of prodrugs or inacti- N
A
vation of drugs (MOC-2), changes in molecular targets (MoC-3), increase in D /
H
the efficacy of processes for repairing macromolecules attacked by cytostatic E
agents (MOC-4) and changes in the apoptosis (MOC-5a) and survival (MOC- ER
IB
5b) balance. Earlier CIBERehd studies identified gene expression patterns C

characteristic of each type of tumor and have indicated possible targets that 25
must be studied for therapeutic purposes.